Last reviewed · How we verify
Placebo of Darbepoetin alfa
Placebo of Darbepoetin alfa is a Erythropoiesis-stimulating protein Small molecule drug developed by Bayer. It is currently in Phase 3 development for Anemia associated with chronic kidney disease, Anemia associated with cancer chemotherapy.
Darbepoetin alfa is an erythropoiesis-stimulating protein that mimics the action of erythropoietin to stimulate red blood cell production.
Darbepoetin alfa is an erythropoiesis-stimulating protein that mimics the action of erythropoietin to stimulate red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia associated with cancer chemotherapy.
At a glance
| Generic name | Placebo of Darbepoetin alfa |
|---|---|
| Sponsor | Bayer |
| Drug class | Erythropoiesis-stimulating protein |
| Target | Erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Hematology |
| Phase | Phase 3 |
Mechanism of action
Darbepoetin alfa works by binding to the erythropoietin receptor on the surface of red blood cell precursors, triggering a cascade of intracellular signaling events that ultimately lead to increased red blood cell production. This is particularly useful in patients with anemia associated with chronic kidney disease or cancer chemotherapy.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia associated with cancer chemotherapy
Common side effects
- Increased risk of thromboembolic events
- Hypertension
- Headache
Key clinical trials
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Darbe Administration in Newborns Undergoing Cooling for Encephalopathy (PHASE1, PHASE2)
- Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) (PHASE3)
- Mild Encephalopathy in the Newborn Treated With Darbepoetin (PHASE2)
- Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration (PHASE2)
- Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin
- Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy (PHASE3)
- Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Darbepoetin alfa CI brief — competitive landscape report
- Placebo of Darbepoetin alfa updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Placebo of Darbepoetin alfa
What is Placebo of Darbepoetin alfa?
How does Placebo of Darbepoetin alfa work?
What is Placebo of Darbepoetin alfa used for?
Who makes Placebo of Darbepoetin alfa?
What drug class is Placebo of Darbepoetin alfa in?
What development phase is Placebo of Darbepoetin alfa in?
What are the side effects of Placebo of Darbepoetin alfa?
What does Placebo of Darbepoetin alfa target?
Related
- Drug class: All Erythropoiesis-stimulating protein drugs
- Target: All drugs targeting Erythropoietin receptor
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Oncology, Hematology
- Indication: Drugs for Anemia associated with chronic kidney disease
- Indication: Drugs for Anemia associated with cancer chemotherapy
- Compare: Placebo of Darbepoetin alfa vs similar drugs
- Pricing: Placebo of Darbepoetin alfa cost, discount & access